InflaRx
Yahoo Finance • 10 days ago
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late... Full story
Yahoo Finance • 14 days ago
InflaRx receives Nasdaq notification
* InflaRx (IFRX [https://seekingalpha.com/symbol/IFRX]) said [https://seekingalpha.com/pr/20437308-inflarx-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement] on Friday it had received a notice from Nas... Full story
Yahoo Finance • 14 days ago
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notic... Full story
Yahoo Finance • 4 months ago
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (W... Full story
Yahoo Finance • 5 months ago
After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers
(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates.... Full story
Yahoo Finance • 5 months ago
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CETCompany also expects to publish third quarter 2025 financial results on the same day pre-market JENA, Germany, Nov. 07, 2025... Full story
Yahoo Finance • 5 months ago
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim S... Full story
Yahoo Finance • 6 months ago
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received... Full story
Yahoo Finance • 7 months ago
Top movers analysis one hour before the close of the markets on 2025-08-29: top gainers and losers in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GMHS... Full story
Yahoo Finance • 7 months ago
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GMHS [https://www.chartmill.com/stock/quote/GMHS/profile] 93.89%... Full story
Yahoo Finance • 7 months ago
InflaRx Announces Participation in September Investor Conferences
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor c... Full story
Yahoo Finance • 8 months ago
InflaRx reports Q2 results
* InflaRx press release [https://seekingalpha.com/pr/20192936-inflarx-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:IFRX [https://seekingalpha.com/symbol/IFRX]): Q2 For the six months ended June 30,... Full story
Yahoo Finance • 8 months ago
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody... Full story
Yahoo Finance • 8 months ago
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its seco... Full story
Yahoo Finance • 9 months ago
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule
* InflaRx N.V. (NASDAQ:IFRX [https://seekingalpha.com/symbol/IFRX]) received a Nasdaq notice for falling below the $1 minimum bid price for 30 consecutive business days. * The company has 180 calendar days, until January 7, 2026, to re... Full story
Yahoo Finance • 9 months ago
InflaRx receives nasdaq notice for minimum bid price requirement
JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), currently trading at $0.88 with a market capitalization of ~$61 million, has received a written notice from Nasdaq indicating that the company’s share price has fallen below the minimum $1.00 per... Full story
Yahoo Finance • 10 months ago
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Comm... Full story
Yahoo Finance • 10 months ago
InflaRx to Participate in Upcoming Investor Conferences
JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in m... Full story
Yahoo Finance • 11 months ago
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company... Full story
Yahoo Finance • last year
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenos... Full story
